Discovering New Innovations in Oncology

David holds a PhD in Molecular Biology and has spent nearly 20 years developing nucleic acid aptamers against a wide variety of targets including small molecules (antibiotics, food contaminants, chemotherapeutics), disease-associated proteins, several cancer-associated cell-lines, viruses and tissue biopsies. This work has been facilitated through the use of high-throughput, automated aptamer selection methods. David has built up an established international reputation in the field and has authored several peer-reviewed research articles, invited review articles and a book chapter on aptamer-based therapeutics. He has also given many guest seminars covering aptamer-based applications at top universities and international conferences.

After beginning her research career at the University of Michigan, Cathie received her Ph.D. at the University of Louisville School of Medicine before completing her post-doctoral fellowship at the Wistar Institute and the University of Pennsylvania. With a career that spans over 20 years at the bench, as well as a Director and a Global Product Manager, all involving the use of biospecimens in the fields of cancer, immunology and virology, Cathie is now Senior Director of Product Marketing, Personalized Medicine, at BioIVT.

Henry Sebesta is a dedicated life sciences industry professional with over 5 years of experience in gene therapy product and business development. Through years of market analysis and direct collaboration with thought leaders across the industry, Mr. Sebesta has helped guide the development of KromaTiD's full suite of gene and cell therapy solutions. He is also a contributing author on KromaTiD's 'dGH for Gene Editing' publication currently under review, and co-inventor on KromaTiD's most recent IP for determining genotoxicity and relative risks of cell and gene therapies.